Dermal Studies at CBI

Similar documents
Hypertrophic scar formation in rabbits

Thermal Burn Modeling in Göttingen Minipigs

CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION RADIOLABEL MASS BALANCE DMPK OVERVIEW XENOGRAFT MODELS ADME SUMMARY REPORT.

Your bridge to. better medicines

TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT

Comparative Oncology Program

DMPK Overview. QPS is your Global Link to all your DMPK Sourcing Needs DMPK OVERVIEW CYP INDUCTION QWBA PROTEIN BINDING CYP INHIBITION

Medical Device Testing. Andrew Makin, MSc, ERT, MRSB Scientific Director CiToxLAB Scantox, Denmark

ICH CONSIDERATIONS Oncolytic Viruses

ICH Considerations. Oncolytic Viruses September 17, 2009

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

Antibody Discovery at Evotec

Guide to Services Our service map.

Eurofins ADME BIOANALYSES Your partner in drug development

Regulatory Issues and Drug Product Approval for Biopharmaceuticals

In Vivo Programs. Contract Research Services. Programs

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Agreed with W. Cornell Graduate Program and Tri-I

The Aptuit Center for Drug Discovery & Development Verona, Italy

Natural Products and Drug Discovery

LAB EXPERTS AT YOUR SIDE Over twenty years of experience

Point-of-Care Cell Processing Devices A Manufacturer s Perspective Clinical trials, regulatory compliance, and commercialization.

Anika Therapeutics, Inc.

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS

THE ANSWERS YOU NEED ARE ALL RIGHT HERE

Industry Academic Collaboration: A Key to Successful Involvement of Patients Early in Clinical Development

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Chemon. Solution for New Drug Development

RXi Pharmaceuticals Corporation

Supplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester

Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

Preclinical study. Assist.Prof. Witthawat Wiriyarat Faculty of Veterinary Science, Mahidol University

Regulatory Issues in Human Subjects Research

Engage with us on Twitter: #Molecule2Miracle

Spray-on stem cells for rapid healing.

THERAPEUTIC AREAS CARDIOVASCULAR RESEARCH

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Guideline for the conduct of efficacy studies for nonsteroidal anti-inflammatory drugs

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS

Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology

"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia

SAFETY RESEARCH INSTITUTE FOR CHEMICAL COMPOUNDS CO., LTD.

06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND

AT A GLANCE. inventivhealthclinical.com

Supplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester

Clean pigs for clear results

fact sheet 3 Introduction to Biosimilars & Regulatory Requirements

Technology Development Funding Program Round 3

Annex VIIIB Paragraphs to be included in the Informed Consent Form for the collection and use of biological samples in clinical trials

Clinical Development of RXI-109 to Reduce Dermal Scarring

NON-CLINICAL LOCAL TOLERANCE TESTING OF MEDICINAL PRODUCTS

Services for Medical Devices. Expert solutions for product development from concept to commercialization

Guide to Services Our service map

The 3Rs: are Human Stem Cells and Organs on Chip alternatives?

Optimisation de votre programme de développement

SUMMARY OF PRODUCT CHARACTERISTICS

We set things in motion and keep them moving. Metronomia Clinical Research Services

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

Injectable modified release products

Successful Academia-Pharma Collaboration Drug Discovery and Clinical Development

the PLATFORM Pipeline in Lyon AREA

Toxicology - Problem Drill 24: Toxicology Studies in Pharmaceutical Development

TECHNOLOGY READINESS LEVELS (TRLs)

A drug development crossroad lies ahead

SKIN BIOLOGY A VALUABLE TOOL FOR THE INNOVATION AND DEVELOPMENT OF NOVEL THERAPEUTIC ALTERNATIVES IN DERMATOLOGY

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices

Preclinical Development Discovery to IND

Adis Journals and Newsletters The premier collection of drug-focused medical journals

Drug Delivery Forum 2018

Dermal drug testing. Pharmacokinetic, pharmacodynamic and bioequivalence studies in the dermis

Dr. S. Harinarayana Rao

May 23, :30 PM-5:00 PM - AUDITORIUM A250. May 9, :30 PM -5:00 PM - AUDITORIUM A-950 May 16, :30 PM-5:00 PM - AUDITORIUM A250

Structure and content of an IMPD. What is required for first into man trial?

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016

The Exploratory IND (Phase 0) Concept

QPS Neuropharmacology Overview

Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Biocompatibility: a risk based approach

Abstracts. Symposium Development and Regulatory Aspects of Topical Dermatics Today

Regulatory Perspective

Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA

CONTENTS. The bottleneck in Drug Discovery. Syncrosome s Preclinical Offer. In short. Drug Efficacy services. Key facts. Bioavailibility and CNS-PK

INSTRUCTIONS FOR COMPLETION OF THE CCAC ANIMAL USE DATA FORM

Explore the World of End-to-End. Integrated Lab Performance

Micar Innovation. Drug Discovery Factory for novel drug molecules

Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date

Radiography Curriculum Analysis

What can be done from regulatory side?

Specialty Lab Services. Deep science at scale

Stem Cell Research: Identifying emerging high priority policy issues

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Monitoring the Safety of Stem Cell Based Therapeutics in Clinical Trials. Jane Lebkowski Ph.D. ASGCT May 18, 2010

Guideline on the non-clinical requirements for radiopharmaceuticals

THE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences

PIP s Pup s and Problems

Transcription:

Dermal Studies at CBI Comparative Biosciences, Inc. 786 Lucerne Drive Sunnyvale, CA 94085 Telephone: 408.738.9260 www.compbio.com

Premier Preclinical Contract Research Organization Over 20 years of experience Conveniently located in the heart of Silicon Valley, amidst many biotech companies State of the art, purpose-built facility Approximately 30 employees Highly experienced staff GLP, OECD, FDA, USDA, OLAW AAALAC Accreditation

Dermal Test Articles Topical-intact and abraded skin; wounds, burns Covered vs Exposed Applications Intradermal Subcutaneous Systemic Numerous Classes of Compounds Small molecules Biologics Stem cells & cell therapies Devices Device and drug combinations Regenerative medicine-stem cells

Dermal Toxicology Studies Topical, systemic, normal and abraded Intact skin, wounds, burns, other pharmacology components GLP and Non-GLP studies Single & multiple dose studies All routes of administration Acute & chronic studies Discovery and Investigative toxicology Local Irritation, Buehler sensitization Complete, prompt reports

Pharmacokinetic Studies GLP and Non-GLP studies Assessment of blood, tissue biopsies Single or multiple dose studies Sample analysis from blood, urine, feces, tissue biopsies Bioanalytical method development Measure Cmax, Tmax, AUC WinNonlin PK/PD Modeling Metabolic and pharmacodynamic studies Non-standard routes of administration

Dermatology Pharmacology and Efficacy Studies Dermatology pharmacology and efficacy modeling Custom model development Surgical modeling Investigative studies Combination GLP efficacy and toxicology

Pharmacology and Efficacy Studies Scar formation-hypertrophic scar Thermal burns UV light burns Wound healing and scarring Local and topical irritation Allergic and immune mediated studies-dth Bleomycin fibrotic: skin and lung Anti-infective dermal studies Dermal xenografts Local sensitization and Buehler Regenerative, stem cell medicine Custom model development SKH1 Hairless Mouse

Typical Study Parameters CBI s experience gives you a number of options Daily clinical observations Daily to weekly body weights Food consumption Clinical pathology Draize scoring Photography and scoring Toxicokinetics or pharmacokinetic Surgical biopsies throughout study Necropsy Histopathology on biopsies and necropsy: Tissue stained with HE, trichrome, other stains upon request IHC for various markers upon request Digital image analysis for wound size, cellular infiltrates, inflammatory markers or other markers Photomicroscopy

Minipig Topical Dermal Studies Minipigs dermal structure recognize as most clinically similar Topical dosing can be tailor to fit clinical study design with 10%BSA typically treated Ease of handling with Minipig, ~15-20kg

Service and Quality The people at CBI from the executive team to the study directors to the research associates expect to have to earn your trust and business. Our ratio of scientists to non-scientists is one of the highest in the industry. We believe in sound science and every study director is a PhD-level scientist Thoroughness in planning and execution is key to a successful study. All protocols are vetted and approved by multiple personnel. Our QAU has a rigorous training program. All non-glp studies are conducted in the spirit of GLP. We believe in communication: timely responses to your inquiries and frequent updates on your study are mandatory. You are always welcome at CBI to meet the staff, tour the laboratory and discuss the progress and results of your study.

Our Staff Study Directors PhD level scientists Appointed by management for each job Serves as single point of control and is responsible and accountable for study conduct and scientific interpretation Experienced attentive and communicative Rapid study initiation and report preparation Research Associates Bachelor Level Scientists Extensive technical training Quality Assurance Full time, dedicated Rigorous training program CBI Management Experienced senior scientific management-with large and small pharma experience

Summary With a focus on skin, CBI provides state of the art: Toxicology Pharmacokinetics Efficacy Pharmacology In house histopathology Experienced attentive and communicative study directors Rapid study initiation and report preparation Established, stable business Regulatory compliance Favorable pricing structure